Table 1.

Summary of SPR Technology Applied in the Nanoparticle Studies

Nanoparticles Type	Analyte	Immobilized Agent	Application	References
Liposomes	Different composed liposomes	Aβ1-42 fibrils	Properties characterization	[33]
Liposomes	PEGs liposome	HSA, ApoE, α2-M, β2-G, Fn	Properties characterization	[34]
Liposome	Glucose	Glucose-imprinted liposomes	Drug Development and Screening	[35]
Liposome	PEG-Liposome, RGD-Liposome, TH-Liposome	Integrin αvβ3	Drug Development and Screening	[36]
Liposomes	bFGF, bFGFp-liposome, bFGFp-liposome + bFGF	FGFR1	Drug binding properties	[37]
Liposomes	Anti-MUC-1- Temperature-sensitive liposomes	Scrambled MUC-1	Drug binding properties	[38]
Liposomes	Anti-ephrin A2- Liposomes	Ephrin A2 extracellular domain	Drug binding properties	[39]
Liposomes	PEGylated liposomes	G-CSF, FVIII, FVIIa	Drug binding properties	[40]
Liposome	hCD40L + peptide	CD40	Drug binding properties	[41]
Liposome	Cyclic RGD motifs-liposomes	Melanoma B16 and MCF-7 cells	Mechanism of drug therapy	[42]
Liposomes	Cationic liposomes	S. mutans biofilm	Mechanism of drug therapy	[43]
Liposomes	BsmAb hMN14x734	Types of liposomes	Properties characterization	[44]
Liposome	Nex-1	Different liposomes	Drug Development and Screening	[45]
Liposome	Etx	Different liposomes	Drug Development and Screening	[46]
Liposome	Salmeterol and propranolol	Liposome	Mechanism of drug therapy	[47]
Liposome	Sulfated 3-O-octadecyl-(1→6)-α-D- glucopyranan, sulfated alkyl maltoheptaoside	Liposome	Mechanism of drug therapy	[48,49]
Liposome	Detergent	Liposome	Mechanism of drug therapy	[50]
Liposome	NRG1+ ErbB4-coated liposomes	Biotin Anti-IgG-Fc	Extension Applications	[51]
Liposome	sfGFP-ANXV, ANXV, sfGFP	Phospholipid liposomes	Extension Applications	[52]
Liposome	OptoPB, V416 variants	POPC liposomes	Extension Applications	[53]
Liposomes and lipid nanoparticle	Anti-CD163 antibody- Liposomes, Anti-CD163 antibody lipid nanoparticle	CD163	Drug binding properties	[54,55]
Lipid nanoparticle	Anti-HB-EGF-modified LNP-siRNA	rhHB-EGF	Drug binding properties	[56]
Lipid Nanoparticle	HA- Lipid Nanoparticle	CD44-Fc chimera	Properties characterization	[57]
Liposome membranes	Cry4Ba-DIII truncate Cry4Ba full-length toxin	Liposome membranes	Drug binding properties	[58]
Nanoliposomes	Curcumin-nanoliposomes	Aβ1-42 monomers or fibrils	Properties characterization	[59]
SMA liposomes	Potential P-gp inhibitor	SMALPs-MCF-7, SMALPs MCF-7/ADR	Extension Applications	[60]
Lipid Salipro nanoparticles	Carbenoxolone, spironolactone, benzoylbenzoyl-ATP	His/Biotin-Salipro-empty, His/Biotin-Salipro-mPANX1	Extension Applications	[61]
Exosomes	Rituximab obinutuzumab	CD20 exosome	Extension Applications	[62]
Exosomes	InP/ZnS-AB + EBC-derived EVs	Goat anti-Mouse IgG1	Extension Applications	[63]
Engineered exosome	PD1-exosome	PDL1	Drug Development and Screening	[64]
Polycationic Albumin Nanoparticles	HAS, lipopolysaccharides	HSA and PEG (2000)18-cHSA	Properties characterization	[65]
Molecularly imprinted nanoparticles	Andarine, Ligandrol, RAD-140	Different SARMs nanoMIPs.	Extension Applications	[66]
PAMAM-based nanoparticles	Folic acid- PAMAM-based nanoparticles	Folic Binding Protein	Properties characterization	[67]
MIP nanoparticles	Trypsin-specific MIP nanoparticles	Trypsin	Properties characterization	[68]
Spike trimer-ferritin fusion recombinant protein nanoparticle	Sera of mice	S-2P and RBD	Drug Development and Screening	[69]
Kappa spike and RBD mRNA-LNP	SARS-CoV-2 BA.1, BA.2 RBD protein	K-RBD chAbs	Drug Development and Screening	[70]
N-S1 protein double-layered nanoparticle	Soluble S1 protein, N-S1 PNp	ACE2-His	Drug Development and Screening	[71]
Mosaic receptor-binding domain (RBD) nanoparticle	Mosaic_RBD-NP	hACE2	Drug Development and Screening	[72]
Polypeptide-based nanoparticles	Nanoparticles Self-assembling polymers	Bacterial cells	Mechanism of drug therapy	[73]
Adamantane derivatives self-assembled nanoparticles	SNPs	Biotinylated melittin	Drug Development and Screening	[74]
Chitosan nanoparticles	Transferrin-modified chitosan nanoparticles	His-tagged Transferrin receptor	Drug binding properties	[75]
Protein nanoparticle	Albumin peptides, Bevacizumab, Rituximab, and Trastuzumab	Rituximab, albumin peptides	Drug binding properties	[76,77]
Gd-chelated polysiloxane nanoparticles	AGuIX NPs, AGuIX@A12 VHH, AGuIX@A4 VHH	PD-L1 and CD47	Extension Applications	[78]
rPAA-Chol nanoparticles	rPAA-Chol nanoparticles	Liposomes	Mechanism of drug therapy	[79]
Nanobody	aSA3 and aRBD-2	RBD	Drug binding properties	[80]
PFC nanoparticles	NBD-Linker	PFC nanoparticle	Mechanism of drug therapy	[81]
Biotin-FNPs	PSA + Ab2-SA-biotin-FNP	Ab1	Extension Applications	[82]
HA-PEI-coated ECH-Zn (PPzn)	ECH-Zn	STAT2, MDM2, STAT2600−750, STAT2Δ600−750	Drug binding properties	[83]
Silica nanoparticles	Biotinylated- silica nanoparticles	Streptavidin	Properties characterization	[84]
AuNPs, silica NPs	SAgs +anti-SEG Abs coupled nanoparticles	Purified antibodies	Extension Applications	[85]